This website is intended for an international audience. To view your own country’s website if available, please select your country from the list provided.
Close
Close
Close
Close
Close
Close

Our diverse portfolio helps us deliver on our commitment to Women's Health

22 June 2021

Pride Month Celebrated at Theramex

With Pride Month in full swing, Theramex, a UK based pharmaceutical company dedicated to women’s health, is celebrating Pride virtually among its Global employees.

London 22nd June – While the pandemic has forced many Pride events to be postponed, Theramex is bringing its celebrations online, taking the opportunity to thank LGBTQIA+ employees across the globe for their tireless contribution to the continuing success of the business.

Pride represents self-acceptance, resilience, dignity, equality and most importantly LOVE. Pride can teach us the importance of self-love and a world where everyone is accepted for who they are. Theramex truly champions all LGBTQIA+ people and understands how important it is to replicate the Pride values into the workplace culture.

“At Theramex, we are committed to a workplace that values diversity, equity, inclusion, and respect for all our LGBTQIA+ colleagues. We strive to create a safe space globally where our employees can be their authentic self without fear of prejudice. Theramex understands the value diversity can have in creating an engaging culture and values the diversity of opinions which helps drive our business forward. Theramex continues to create a culture that represents the diversity of our modern World today.” – Robert Stewart CEO

12 July 2021

Theramex appoints Sigurd Kirk to the Board of Directors

Read more

10 June 2021

Theramex UK Ltd announces a license and supply agreement with Enzene Biosciences Limited, for the registration and commercialisation of denosumab, an antiresorptive treatment for osteoporosis, a biosimilar of reference medicine Prolia®, in Europe, the UK, Switzerland, and Australia

Read more